The echinocandins: three useful choices or three too many?

被引：36

作者：

Bal, A. M. ^{[1
]}

机构：

[1] NHS Ayrshire & Arran, Crosshouse Hosp, Dept Med Microbiol, Kilmarnock KA2 0BE, Scotland

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2010年 / 35卷 / 01期

关键词：

Anidulafungin; Antifungal prophylaxis; Candidaemia; Caspofungin; Febrile neutropenia; Invasive aspergillosis; Micafungin; Oesophageal candidiasis; LIPOSOMAL AMPHOTERICIN-B; INVASIVE FUNGAL-INFECTIONS; CANDIDA-ALBICANS BIOFILMS; DOUBLE-BLIND TRIAL; IN-VITRO ACTIVITY; EMPIRICAL ANTIFUNGAL THERAPY; COST-EFFECTIVENESS ANALYSIS; PULMONARY ASPERGILLOSIS; PERSISTENT FEVER; ESOPHAGEAL CANDIDIASIS;

D O I：

10.1016/j.ijantimicag.2009.09.011

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Echinocandins act by inhibiting 1,3-beta-D-glucan synthesis in the fungal cell wall. The three licensed agents in this class, namely anidulafungin, caspofungin and micafungin, have a favourable pharmacological pro. le. These agents are narrow spectrum with clinically relevant activity against Candida and Aspergillus spp. Several trials have established the non-inferiority of these agents over existing agents in the treatment of invasive fungal infections. Caspofungin is also licensed for empirical antifungal therapy of presumed fungal infections in patients with febrile neutropenia. This paper reviews the literature on echinocandins. (c) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：13 / 18

页数：6

共 69 条

[1]

Azanza Jose Ramon, 2008, Enferm Infecc Microbiol Clin, V26 Suppl 14, P14

[2]

AZANZA JR, 2009, ENFERM INFEC MICR CL, V27, P138

[3] Early clinical experience with anidulafungin at a large tertiary care medical center [J].

Brielmaier, Benjamin D. ;

Casabar, Ed ;

Kurtzeborn, Christine M. ;

McKinnon, Peggy S. ;

Ritchie, David J. .

PHARMACOTHERAPY, 2008, 28 (01) :64-73

[4] A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK [J].

Bruynesteyn, Karin ;

Gant, Vanya ;

McKenzie, Catherine ;

Pagliuca, Tony ;

Poynton, Chris ;

Kumar, Ritesh N. ;

Jansen, Jeroen P. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (06) :532-539

[5] In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth [J].

Cateau, Estelle ;

Rodier, Marie-Helene ;

Imbert, Christine .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (01) :153-155

[6] Micafungin: A new echinocandin [J].

Chandrasekar, PH ;

Sobel, JD .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) :1171-1178

[7] Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals [J].

Choi, Hyun Woo ;

Shin, Jong Hee ;

Jung, Sook In ;

Park, Kyung Hwa ;

Cho, Duck ;

Kee, Seung Jung ;

Shin, Myung Geun ;

Suh, Soon Pal ;

Ryang, Dong Wook .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1520-1523

[8] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Winston, Drew J. ;

Perfect, John ;

Ullmann, Andrew J. ;

Walsh, Thomas J. ;

Helfgott, David ;

Holowiecki, Jerzy ;

Stockelberg, Dick ;

Goh, Yeow-Tee ;

Petrini, Mario ;

Hardalo, Cathy ;

Suresh, Ramachandran ;

Angulo-Gonzalez, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359

[9] Pharmacokinetics and tissue distribution of anidulafungin in rats [J].

Damle, Bharat ;

Stogniew, Martin ;

Dowei, James .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2673-2676

[10]

DEMCHOK JP, 2009, MYCOSES

← 1 2 3 4 5 6 7 →